^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IGFBP7-AS1 rs4516785

    i
    Other names: IGFBP7-AS1, IGFBP7 Antisense RNA 1, NONHSAG038024.2, HSALNG0034634, HSALNG0034636, IGFBP7-AS1
    Entrez ID:
    255130
    Related biomarkers:
    Mutation
    over2years
    Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC (IASLC-WCLC 2023)
    Half of the patients (50%) received ICI monotherapy, whilst the other half had chemotherapy-ICI combination, 1 patient received Nivolumab-ipilimumab combination...Pembrolizumab (75%), Atezolizumab (12%) and Nivolumab (7%) were the most common ICIs prescribed... This GWAS pharmacogenomic study identified 7 novel variants in 4 genes associated with ICI response in advanced NSCLC. Current efforts are ongoing through validation in an independent patient cohort. These unique gene signatures, when validated and confirmed, may prove to be valuable tools in predicting ICI response in patients with advanced NSCLC.
    Clinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    IGFBP7-AS1 (IGFBP7 Antisense RNA 1) • BMP6 (Bone Morphogenetic Protein 6) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7) • LDLRAD4 (Low Density Lipoprotein Receptor Class A Domain Containing 4) • LINC02468 (Long Intergenic Non-Protein Coding RNA 2468) • LINC02751 (Long Intergenic Non-Protein Coding RNA 2751)
    |
    PD-L1 expression • PD-L1 overexpression • BMP6 rs267807 • IGFBP7-AS1 rs10033422 • IGFBP7-AS1 rs4516785 • IGFBP7-AS1 rs6828212 • LDLRAD4 rs16940509 • LINC02468 rs10841449 • LINC02751 rs1872285
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab)